---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-055272"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2022-05-03T23:59:59+00:00"
generated_at: "2026-06-26T01:11:15.606265+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rigel Q1 net loss $27.4M vs prior-year net income; TAVALISSE sales up 31%

## Summary
- Net loss of $27.4M ($0.16/sh) vs net income of $39.5M ($0.23/sh) in Q1 2021.
- Total revenues $16.7M: TAVALISSE net product sales $16.2M (+31% YoY); contract revenues $0.5M.
- Cash and short-term investments $107.5M at March 31, down from $125.0M at Dec 31, 2021.
- FORWARD Phase 3 wAIHA trial topline data expected mid-2022; potential first-to-market therapy if approved.
- COVID-19 fostamatinib trial enrolled 268 of 308 patients; evaluating completion strategies.

## SEC filing metadata
- accession: 0001104659-22-055272
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2022-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465922055272/0001104659-22-055272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465922055272/tm2214228d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-055272
- JSON: https://secwatch.observer/filing/0001104659-22-055272.json
- Plain text: https://secwatch.observer/filing/0001104659-22-055272.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.